Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avivit Peer

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Nutrients|December 28, 2021
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.
Cancer Research and Treatment|March 13, 2015
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?Daniel Keizman, Keren Rouvinov, Avishay Sella, et al.
Nutrients|August 26, 2023
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
JAMA Oncology|July 8, 2021
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for CancerTal Goshen-Lago, Ithai Waldhorn, Roy Holland, et al.
Cancer Discovery|September 3, 2021
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid TumorsIthai Waldhorn, Roy Holland, Tal Goshen-Lago, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2012
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinomaDaniel Keizman, Maya Ish-Shalom, Roberto Pili, et al.
The Oncologist|January 20, 2025
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancerEmiliano Calvo, Bernard Doger, Joan Carles, et al.
Clinical Genitourinary Cancer|May 24, 2016
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell CarcinomaDaniel Keizman, Maya Ish-Shalom, Avishay Sella, et al.
European Urology Open Science|November 10, 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer RegistryAnders Bjartell, Luis Costa, Gero Kramer, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Nutrients|December 28, 2021
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.
Cancer Research and Treatment|March 13, 2015
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?Daniel Keizman, Keren Rouvinov, Avishay Sella, et al.
Nutrients|August 26, 2023
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
JAMA Oncology|July 8, 2021
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for CancerTal Goshen-Lago, Ithai Waldhorn, Roy Holland, et al.
Cancer Discovery|September 3, 2021
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid TumorsIthai Waldhorn, Roy Holland, Tal Goshen-Lago, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2012
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinomaDaniel Keizman, Maya Ish-Shalom, Roberto Pili, et al.
The Oncologist|January 20, 2025
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancerEmiliano Calvo, Bernard Doger, Joan Carles, et al.
Clinical Genitourinary Cancer|May 24, 2016
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell CarcinomaDaniel Keizman, Maya Ish-Shalom, Avishay Sella, et al.
European Urology Open Science|November 10, 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer RegistryAnders Bjartell, Luis Costa, Gero Kramer, et al.
Pageof 5